Ergothioneine Supplement for Kidney Failure Patients
This study is testing whether a daily supplement of ergothioneine can restore its levels in the blood of people with kidney failure (ESRD) who are on dialysis. Dialysis can remove important chemicals like ergothioneine, which is often low in these patients. Participants will receive either an ergothioneine capsule or a placebo capsule daily for 12 weeks. The main goal is to see how much ergothioneine levels in red blood cells change over time. You may be able to join if you are 18 or older, have kidney failure, and are on hemodialysis or peritoneal dialysis. We are looking to enroll 28 participants.
- Study design
- This study is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 28 participants.
- What's involved
- Participants will take a capsule daily for 12 weeks. Blood tests will be done at weeks 1, 2, 4, 8, 12, 16, and 20.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 8 weeks after stopping the ergothioneine or placebo, with blood tests at weeks 16 and 20.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Repletion of Ergothioneine in Patients With Kidney Failure
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Tammy Sirich, MD · PRINCIPAL_INVESTIGATOR · Stanford University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- erythrocyte levels of ergothioneineweeks 1, 2, 4, 8, and 12 (while taking ergothioneine or placebo); and weeks 16 and 20 (after stopping ergothioneine or placebo)
ergothioneine levels will be measured in whole blood